Wednesday, 14th October 18th International Symposium on Dendritic Cells 2026

• The exceptionalism of the cDC1 lineage and its central role in tumor immunity - Miriam Merad

Panellists include:

• Edgar Engleman
• Miriam Merad
• Filipe Pereira

• CCR7⁺ activated dendritic cells: defining the state that drives cancer immunity - Santiago Zelenay
• On the Nature of Antigen Uptake and Presentation in the TME - Max Krummel
• The tumor-sentinel lymph node immuno-migratome reveals CCR7⁺ dendritic cells drive response to sequenced immunoradiotherapy - Robert Saddawi-Konefka
• Context‑Dependent DC2 States in Human Cancer - Kristen Radford
• Dendritic-Cell Spatial Organization Shapes Tissue Immunity - Christine Moussion
• Regulation of anti-cancer immunity by a natural killer cell - dendritic cell innate immune axis.  - Kevin C Barry
• CAR-DC1: A novel next-generation dendritic cell therapy for targeting solid tumours - Devi Jenika

• Next-gen DC1 immunotherapy: Making the theoretical possible - Shalin Naik
• Inducing lymphoid niches across cancers by tumor-to-dendritic cell reprogramming - Filipe Pereira
• Using mRNA-LNP technology to manipulate conventional dendritic cell biology - Justine Mintern
• Spatiotemporal Coordination of NK Cells and CTLs Drives Remodeling of Poorly T Cell–Infiltrated Tumor Microenvironments - Shin-ichiro SF Fujii
• CD28 Costimulatory Bispecifics Synergize with Chemotherapy and ADCs to Broaden Antitumor T Cell Immunity - Bei Wang
• Ongoing Survival Analysis of DOC1021 for Treatment of Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma - William K Decker
• Regulating myeloid cells to promote mature tertiary lymphoid structures and enhance anti-tumor immunity - Elizabeth E Evans